<?xml version="1.0"?>
<rss version="2.0" xmlns:prism="http://purl.org/rss/1.0/modules/prism/">
  <channel>
    <title>JAMA Surgery: Pruritus Topic Collection</title>
    <link>http://archsurg.jamanetwork.com/</link>
    <description>
    </description>
    <language>en-us</language>
    <pubDate>Wed, 26 Dec 2012 00:00:00 GMT</pubDate>
    <lastBuildDate>Tue, 01 Jan 2013 00:51:15 GMT</lastBuildDate>
    <generator>Silverchair</generator>
    <managingEditor>editor@archsurg.jamanetwork.com</managingEditor>
    <webMaster>webmaster@archsurg.jamanetwork.com</webMaster>
    <item>
      <title>Influence of Histamine Receptor Antagonists on the Outcome of Perforated Appendicitis Analysis From a Prospective Trial  Antihistamine Use and Perforated Appendicitis </title>
      <link>http://archsurg.jamanetwork.com/article.aspx?articleID=405718</link>
      <pubDate>Mon, 01 Feb 2010 00:00:00 GMT</pubDate>
      <author>St. Peter SD, Sharp SW, Ostlie DJ. </author>
      <description>&lt;span class="paragraphSection"&gt;&lt;div class="boxTitle"&gt;Hypothesis&lt;/div&gt;Diphenhydramine blocks the H&lt;sub&gt;1&lt;/sub&gt; receptor to treat pruritus or to induce sleep, while ranitidine blocks the H&lt;sub&gt;2&lt;/sub&gt; receptor to suppress gastric acid. They are often given to ill patients, such as those with perforated appendicitis. However, these receptors are integral to the inflammatory response, and to our knowledge, the impact of H&lt;sub&gt;1&lt;/sub&gt; or H&lt;sub&gt;2&lt;/sub&gt; blockade on outcome in the setting of perforated appendicitis has never been evaluated.&lt;div class="boxTitle"&gt;Design&lt;/div&gt;Prospective randomized trial.&lt;div class="boxTitle"&gt;Setting&lt;/div&gt;Referral center.&lt;div class="boxTitle"&gt;Patients&lt;/div&gt;Children undergoing an operation for perforated appendicitis from April 2005 to November 2006.&lt;div class="boxTitle"&gt;Main Outcome Measures&lt;/div&gt;We conducted multivariate analysis with Pearson correlation on data from a prospective randomized trial comparing antibiotic regimen after appendectomy for perforated appendicitis and outcome. Medications with a significant correlation to abscess development were investigated by comparing those receiving the medication with those who did not using the &lt;span style="font-style:italic;"&gt;t&lt;/span&gt; test for continuous variables and χ&lt;sup&gt;2&lt;/sup&gt; test for discrete variables. Significance was defined as &lt;span style="font-style:italic;"&gt;P&lt;/span&gt; ≤ .05.&lt;div class="boxTitle"&gt;Results&lt;/div&gt;Significant correlations were found between the use of ranitidine (&lt;span style="font-style:italic;"&gt;P&lt;/span&gt; = .05) or diphenhydramine (&lt;span style="font-style:italic;"&gt;P&lt;/span&gt; = .03) and the development of an abscess. Direct comparison found no differences in patient or operative variables in those given either medication compared with those receiving no doses. Abscess rate in those receiving neither medication (n = 41) was 10%. Those given only ranitidine (n = 24) or diphenhydramine (n = 17) had doubled abscess rates of 17% and 18%, respectively. Those given both medications (n = 16) had a quadrupled abscess rate of 44% (&lt;span style="font-style:italic;"&gt;P&lt;/span&gt; = .03).&lt;div class="boxTitle"&gt;Conclusions&lt;/div&gt;Ranitidine or diphenhydramine given to patients with perforated appendicitis may increase the risk of postoperative abscess. Therefore, these medications should not be used empirically in this population.&lt;/span&gt;</description>
      <prism:volume xmlns:prism="prism">145</prism:volume>
      <prism:number xmlns:prism="prism">2</prism:number>
      <prism:startingPage xmlns:prism="prism">143</prism:startingPage>
      <prism:endingPage xmlns:prism="prism">146</prism:endingPage>
      <prism:doi xmlns:prism="prism">10.1001/archsurg.2009.258</prism:doi>
      <guid>http://archsurg.jamanetwork.com/article.aspx?articleID=405718</guid>
    </item>
  </channel>
</rss>